Agile Therapeutics (NASDAQ:AGRX) Stock Price Down 7.9%

Agile Therapeutics Inc (NASDAQ:AGRX) shares dropped 7.9% on Friday . The stock traded as low as $1.23 and last traded at $1.29, approximately 500,635 shares traded hands during mid-day trading. An increase of 35% from the average daily volume of 371,070 shares. The stock had previously closed at $1.40.

AGRX has been the topic of several research reports. ValuEngine lowered Wolverine World Wide from a “hold” rating to a “sell” rating in a research report on Monday, May 20th. Maxim Group set a $3.00 target price on Agile Therapeutics and gave the stock a “buy” rating in a research report on Monday, June 10th. Oppenheimer initiated coverage on Southwestern Energy in a research report on Thursday, June 6th. They issued a “market perform” rating on the stock. Finally, Janney Montgomery Scott initiated coverage on PLx Pharma in a research report on Friday, April 12th. They issued a “buy” rating on the stock. One analyst has rated the stock with a hold rating and four have issued a buy rating to the stock. The company has an average rating of “Buy” and a consensus price target of $4.00.

The company has a quick ratio of 8.91, a current ratio of 8.91 and a debt-to-equity ratio of 0.01. The stock has a market capitalization of $61.24 million, a price-to-earnings ratio of -2.22 and a beta of 0.65. The company has a 50-day simple moving average of $1.36.

Agile Therapeutics (NASDAQ:AGRX) last issued its earnings results on Thursday, May 2nd. The specialty pharmaceutical company reported ($0.13) earnings per share for the quarter, missing the consensus estimate of ($0.11) by ($0.02). Equities research analysts expect that Agile Therapeutics Inc will post -0.44 earnings per share for the current year.

In other news, CEO Alfred Altomari bought 20,000 shares of the business’s stock in a transaction that occurred on Monday, June 10th. The shares were acquired at an average cost of $1.27 per share, with a total value of $25,400.00. Following the transaction, the chief executive officer now owns 258,568 shares of the company’s stock, valued at approximately $328,381.36. The acquisition was disclosed in a filing with the SEC, which is accessible through this hyperlink. Company insiders own 8.50% of the company’s stock.

Several institutional investors and hedge funds have recently modified their holdings of the stock. BlackRock Inc. raised its position in shares of Agile Therapeutics by 15.7% in the 4th quarter. BlackRock Inc. now owns 133,219 shares of the specialty pharmaceutical company’s stock worth $77,000 after buying an additional 18,038 shares during the period. Geode Capital Management LLC raised its position in shares of Agile Therapeutics by 24.0% in the 4th quarter. Geode Capital Management LLC now owns 230,496 shares of the specialty pharmaceutical company’s stock worth $132,000 after buying an additional 44,639 shares during the period. Finally, Acadian Asset Management LLC raised its position in shares of Agile Therapeutics by 33.3% in the 1st quarter. Acadian Asset Management LLC now owns 417,269 shares of the specialty pharmaceutical company’s stock worth $630,000 after buying an additional 104,222 shares during the period. 42.38% of the stock is currently owned by institutional investors and hedge funds.

About Agile Therapeutics (NASDAQ:AGRX)

Agile Therapeutics, Inc, a women's healthcare company, focuses on the development and commercialization of prescription contraceptive products for women. Its lead product candidate is Twirla, also known as AG200-15, a once-weekly prescription contraceptive patch, which completed Phase III clinical trials.

See Also: Trading Ex-Dividend

Receive News & Ratings for Agile Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Agile Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.